Anti-VEGF Medicine Market, Global Outlook and Forecast 2022-2028

August 2022 | 79 pages | ID: AA99010561E3EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Anti-VEGF Medicine in global, including the following market information:

Global Anti-VEGF Medicine Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Anti-VEGF Medicine Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Anti-VEGF Medicine companies in 2021 (%)

The global Anti-VEGF Medicine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Single Target (Ranibizumab, etc.) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Anti-VEGF Medicine include Faricimab, Bayer (Regeneron), Brolucizumab, Kanghong Pharmaceutical and Santen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-VEGF Medicine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anti-VEGF Medicine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-VEGF Medicine Market Segment Percentages, by Type, 2021 (%)

• Single Target (Ranibizumab, etc.)
• Multiple Targets (Aflibercept, Conbercept, etc.)

Global Anti-VEGF Medicine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-VEGF Medicine Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Eye Clinic
• Other

Global Anti-VEGF Medicine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-VEGF Medicine Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Anti-VEGF Medicine revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Anti-VEGF Medicine revenues share in global market, 2021 (%)

Key companies Anti-VEGF Medicine sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Anti-VEGF Medicine sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Faricimab
• Bayer (Regeneron)
• Brolucizumab
• Kanghong Pharmaceutical
• Santen

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Anti-VEGF Medicine Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Anti-VEGF Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ANTI-VEGF MEDICINE OVERALL MARKET SIZE

2.1 Global Anti-VEGF Medicine Market Size: 2021 VS 2028
2.2 Global Anti-VEGF Medicine Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Anti-VEGF Medicine Sales: 2017-2028

3 COMPANY LANDSCAPE

3.1 Top Anti-VEGF Medicine Players in Global Market
3.2 Top Global Anti-VEGF Medicine Companies Ranked by Revenue
3.3 Global Anti-VEGF Medicine Revenue by Companies
3.4 Global Anti-VEGF Medicine Sales by Companies
3.5 Global Anti-VEGF Medicine Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Anti-VEGF Medicine Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Anti-VEGF Medicine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Anti-VEGF Medicine Players in Global Market
  3.8.1 List of Global Tier 1 Anti-VEGF Medicine Companies
  3.8.2 List of Global Tier 2 and Tier 3 Anti-VEGF Medicine Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Anti-VEGF Medicine Market Size Markets, 2021 & 2028
  4.1.2 Single Target (Ranibizumab, etc.)
  4.1.3 Multiple Targets (Aflibercept, Conbercept, etc.)
4.2 By Type - Global Anti-VEGF Medicine Revenue & Forecasts
  4.2.1 By Type - Global Anti-VEGF Medicine Revenue, 2017-2022
  4.2.2 By Type - Global Anti-VEGF Medicine Revenue, 2023-2028
  4.2.3 By Type - Global Anti-VEGF Medicine Revenue Market Share, 2017-2028
4.3 By Type - Global Anti-VEGF Medicine Sales & Forecasts
  4.3.1 By Type - Global Anti-VEGF Medicine Sales, 2017-2022
  4.3.2 By Type - Global Anti-VEGF Medicine Sales, 2023-2028
  4.3.3 By Type - Global Anti-VEGF Medicine Sales Market Share, 2017-2028
4.4 By Type - Global Anti-VEGF Medicine Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Anti-VEGF Medicine Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Eye Clinic
  5.1.4 Other
5.2 By Application - Global Anti-VEGF Medicine Revenue & Forecasts
  5.2.1 By Application - Global Anti-VEGF Medicine Revenue, 2017-2022
  5.2.2 By Application - Global Anti-VEGF Medicine Revenue, 2023-2028
  5.2.3 By Application - Global Anti-VEGF Medicine Revenue Market Share, 2017-2028
5.3 By Application - Global Anti-VEGF Medicine Sales & Forecasts
  5.3.1 By Application - Global Anti-VEGF Medicine Sales, 2017-2022
  5.3.2 By Application - Global Anti-VEGF Medicine Sales, 2023-2028
  5.3.3 By Application - Global Anti-VEGF Medicine Sales Market Share, 2017-2028
5.4 By Application - Global Anti-VEGF Medicine Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Anti-VEGF Medicine Market Size, 2021 & 2028
6.2 By Region - Global Anti-VEGF Medicine Revenue & Forecasts
  6.2.1 By Region - Global Anti-VEGF Medicine Revenue, 2017-2022
  6.2.2 By Region - Global Anti-VEGF Medicine Revenue, 2023-2028
  6.2.3 By Region - Global Anti-VEGF Medicine Revenue Market Share, 2017-2028
6.3 By Region - Global Anti-VEGF Medicine Sales & Forecasts
  6.3.1 By Region - Global Anti-VEGF Medicine Sales, 2017-2022
  6.3.2 By Region - Global Anti-VEGF Medicine Sales, 2023-2028
  6.3.3 By Region - Global Anti-VEGF Medicine Sales Market Share, 2017-2028
6.4 North America
  6.4.1 By Country - North America Anti-VEGF Medicine Revenue, 2017-2028
  6.4.2 By Country - North America Anti-VEGF Medicine Sales, 2017-2028
  6.4.3 US Anti-VEGF Medicine Market Size, 2017-2028
  6.4.4 Canada Anti-VEGF Medicine Market Size, 2017-2028
  6.4.5 Mexico Anti-VEGF Medicine Market Size, 2017-2028
6.5 Europe
  6.5.1 By Country - Europe Anti-VEGF Medicine Revenue, 2017-2028
  6.5.2 By Country - Europe Anti-VEGF Medicine Sales, 2017-2028
  6.5.3 Germany Anti-VEGF Medicine Market Size, 2017-2028
  6.5.4 France Anti-VEGF Medicine Market Size, 2017-2028
  6.5.5 U.K. Anti-VEGF Medicine Market Size, 2017-2028
  6.5.6 Italy Anti-VEGF Medicine Market Size, 2017-2028
  6.5.7 Russia Anti-VEGF Medicine Market Size, 2017-2028
  6.5.8 Nordic Countries Anti-VEGF Medicine Market Size, 2017-2028
  6.5.9 Benelux Anti-VEGF Medicine Market Size, 2017-2028
6.6 Asia
  6.6.1 By Region - Asia Anti-VEGF Medicine Revenue, 2017-2028
  6.6.2 By Region - Asia Anti-VEGF Medicine Sales, 2017-2028
  6.6.3 China Anti-VEGF Medicine Market Size, 2017-2028
  6.6.4 Japan Anti-VEGF Medicine Market Size, 2017-2028
  6.6.5 South Korea Anti-VEGF Medicine Market Size, 2017-2028
  6.6.6 Southeast Asia Anti-VEGF Medicine Market Size, 2017-2028
  6.6.7 India Anti-VEGF Medicine Market Size, 2017-2028
6.7 South America
  6.7.1 By Country - South America Anti-VEGF Medicine Revenue, 2017-2028
  6.7.2 By Country - South America Anti-VEGF Medicine Sales, 2017-2028
  6.7.3 Brazil Anti-VEGF Medicine Market Size, 2017-2028
  6.7.4 Argentina Anti-VEGF Medicine Market Size, 2017-2028
6.8 Middle East & Africa
  6.8.1 By Country - Middle East & Africa Anti-VEGF Medicine Revenue, 2017-2028
  6.8.2 By Country - Middle East & Africa Anti-VEGF Medicine Sales, 2017-2028
  6.8.3 Turkey Anti-VEGF Medicine Market Size, 2017-2028
  6.8.4 Israel Anti-VEGF Medicine Market Size, 2017-2028
  6.8.5 Saudi Arabia Anti-VEGF Medicine Market Size, 2017-2028
  6.8.6 UAE Anti-VEGF Medicine Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Faricimab
  7.1.1 Faricimab Corporate Summary
  7.1.2 Faricimab Business Overview
  7.1.3 Faricimab Anti-VEGF Medicine Major Product Offerings
  7.1.4 Faricimab Anti-VEGF Medicine Sales and Revenue in Global (2017-2022)
  7.1.5 Faricimab Key News
7.2 Bayer (Regeneron)
  7.2.1 Bayer (Regeneron) Corporate Summary
  7.2.2 Bayer (Regeneron) Business Overview
  7.2.3 Bayer (Regeneron) Anti-VEGF Medicine Major Product Offerings
  7.2.4 Bayer (Regeneron) Anti-VEGF Medicine Sales and Revenue in Global (2017-2022)
  7.2.5 Bayer (Regeneron) Key News
7.3 Brolucizumab
  7.3.1 Brolucizumab Corporate Summary
  7.3.2 Brolucizumab Business Overview
  7.3.3 Brolucizumab Anti-VEGF Medicine Major Product Offerings
  7.3.4 Brolucizumab Anti-VEGF Medicine Sales and Revenue in Global (2017-2022)
  7.3.5 Brolucizumab Key News
7.4 Kanghong Pharmaceutical
  7.4.1 Kanghong Pharmaceutical Corporate Summary
  7.4.2 Kanghong Pharmaceutical Business Overview
  7.4.3 Kanghong Pharmaceutical Anti-VEGF Medicine Major Product Offerings
  7.4.4 Kanghong Pharmaceutical Anti-VEGF Medicine Sales and Revenue in Global (2017-2022)
  7.4.5 Kanghong Pharmaceutical Key News
7.5 Santen
  7.5.1 Santen Corporate Summary
  7.5.2 Santen Business Overview
  7.5.3 Santen Anti-VEGF Medicine Major Product Offerings
  7.5.4 Santen Anti-VEGF Medicine Sales and Revenue in Global (2017-2022)
  7.5.5 Santen Key News

8 GLOBAL ANTI-VEGF MEDICINE PRODUCTION CAPACITY, ANALYSIS

8.1 Global Anti-VEGF Medicine Production Capacity, 2017-2028
8.2 Anti-VEGF Medicine Production Capacity of Key Manufacturers in Global Market
8.3 Global Anti-VEGF Medicine Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints

10 ANTI-VEGF MEDICINE SUPPLY CHAIN ANALYSIS

10.1 Anti-VEGF Medicine Industry Value Chain
10.2 Anti-VEGF Medicine Upstream Market
10.3 Anti-VEGF Medicine Downstream and Clients
10.4 Marketing Channels Analysis
  10.4.1 Marketing Channels
  10.4.2 Anti-VEGF Medicine Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Anti-VEGF Medicine in Global Market
Table 2. Top Anti-VEGF Medicine Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Anti-VEGF Medicine Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Anti-VEGF Medicine Revenue Share by Companies, 2017-2022
Table 5. Global Anti-VEGF Medicine Sales by Companies, (K Units), 2017-2022
Table 6. Global Anti-VEGF Medicine Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Anti-VEGF Medicine Price (2017-2022) & (US$/Unit)
Table 8. Global Manufacturers Anti-VEGF Medicine Product Type
Table 9. List of Global Tier 1 Anti-VEGF Medicine Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-VEGF Medicine Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Anti-VEGF Medicine Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Anti-VEGF Medicine Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Anti-VEGF Medicine Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Anti-VEGF Medicine Sales (K Units), 2017-2022
Table 15. By Type - Global Anti-VEGF Medicine Sales (K Units), 2023-2028
Table 16. By Application – Global Anti-VEGF Medicine Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Anti-VEGF Medicine Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Anti-VEGF Medicine Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Anti-VEGF Medicine Sales (K Units), 2017-2022
Table 20. By Application - Global Anti-VEGF Medicine Sales (K Units), 2023-2028
Table 21. By Region – Global Anti-VEGF Medicine Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Anti-VEGF Medicine Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Anti-VEGF Medicine Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Anti-VEGF Medicine Sales (K Units), 2017-2022
Table 25. By Region - Global Anti-VEGF Medicine Sales (K Units), 2023-2028
Table 26. By Country - North America Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Anti-VEGF Medicine Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Anti-VEGF Medicine Sales, (K Units), 2017-2022
Table 29. By Country - North America Anti-VEGF Medicine Sales, (K Units), 2023-2028
Table 30. By Country - Europe Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Anti-VEGF Medicine Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Anti-VEGF Medicine Sales, (K Units), 2017-2022
Table 33. By Country - Europe Anti-VEGF Medicine Sales, (K Units), 2023-2028
Table 34. By Region - Asia Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Anti-VEGF Medicine Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Anti-VEGF Medicine Sales, (K Units), 2017-2022
Table 37. By Region - Asia Anti-VEGF Medicine Sales, (K Units), 2023-2028
Table 38. By Country - South America Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Anti-VEGF Medicine Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Anti-VEGF Medicine Sales, (K Units), 2017-2022
Table 41. By Country - South America Anti-VEGF Medicine Sales, (K Units), 2023-2028
Table 42. By Country - Middle East & Africa Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Anti-VEGF Medicine Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Anti-VEGF Medicine Sales, (K Units), 2017-2022
Table 45. By Country - Middle East & Africa Anti-VEGF Medicine Sales, (K Units), 2023-2028
Table 46. Faricimab Corporate Summary
Table 47. Faricimab Anti-VEGF Medicine Product Offerings
Table 48. Faricimab Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 49. Bayer (Regeneron) Corporate Summary
Table 50. Bayer (Regeneron) Anti-VEGF Medicine Product Offerings
Table 51. Bayer (Regeneron) Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 52. Brolucizumab Corporate Summary
Table 53. Brolucizumab Anti-VEGF Medicine Product Offerings
Table 54. Brolucizumab Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 55. Kanghong Pharmaceutical Corporate Summary
Table 56. Kanghong Pharmaceutical Anti-VEGF Medicine Product Offerings
Table 57. Kanghong Pharmaceutical Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 58. Santen Corporate Summary
Table 59. Santen Anti-VEGF Medicine Product Offerings
Table 60. Santen Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 61. Anti-VEGF Medicine Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
Table 62. Global Anti-VEGF Medicine Capacity Market Share of Key Manufacturers, 2020-2022
Table 63. Global Anti-VEGF Medicine Production by Region, 2017-2022 (K Units)
Table 64. Global Anti-VEGF Medicine Production by Region, 2023-2028 (K Units)
Table 65. Anti-VEGF Medicine Market Opportunities & Trends in Global Market
Table 66. Anti-VEGF Medicine Market Drivers in Global Market
Table 67. Anti-VEGF Medicine Market Restraints in Global Market
Table 68. Anti-VEGF Medicine Raw Materials
Table 69. Anti-VEGF Medicine Raw Materials Suppliers in Global Market
Table 70. Typical Anti-VEGF Medicine Downstream
Table 71. Anti-VEGF Medicine Downstream Clients in Global Market
Table 72. Anti-VEGF Medicine Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Anti-VEGF Medicine Segment by Type
Figure 2. Anti-VEGF Medicine Segment by Application
Figure 3. Global Anti-VEGF Medicine Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Anti-VEGF Medicine Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Anti-VEGF Medicine Revenue, 2017-2028 (US$, Mn)
Figure 7. Anti-VEGF Medicine Sales in Global Market: 2017-2028 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Anti-VEGF Medicine Revenue in 2021
Figure 9. By Type - Global Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 10. By Type - Global Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 11. By Type - Global Anti-VEGF Medicine Price (US$/Unit), 2017-2028
Figure 12. By Application - Global Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 13. By Application - Global Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 14. By Application - Global Anti-VEGF Medicine Price (US$/Unit), 2017-2028
Figure 15. By Region - Global Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 16. By Region - Global Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 17. By Country - North America Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 18. By Country - North America Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 19. US Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 24. Germany Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 25. France Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 33. China Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 37. India Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 39. By Country - South America Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 40. Brazil Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Anti-VEGF Medicine Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Anti-VEGF Medicine Sales Market Share, 2017-2028
Figure 44. Turkey Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Anti-VEGF Medicine Revenue, (US$, Mn), 2017-2028
Figure 48. Global Anti-VEGF Medicine Production Capacity (K Units), 2017-2028
Figure 49. The Percentage of Production Anti-VEGF Medicine by Region, 2021 VS 2028
Figure 50. Anti-VEGF Medicine Industry Value Chain
Figure 51. Marketing Channels